MX2018004295A - Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar. - Google Patents
Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.Info
- Publication number
- MX2018004295A MX2018004295A MX2018004295A MX2018004295A MX2018004295A MX 2018004295 A MX2018004295 A MX 2018004295A MX 2018004295 A MX2018004295 A MX 2018004295A MX 2018004295 A MX2018004295 A MX 2018004295A MX 2018004295 A MX2018004295 A MX 2018004295A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- pharmaceutical compositions
- diseases
- ppar agonists
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos y composiciones de utilidad para aumentar la actividad de PPARd. Los compuestos y las composiciones provistos en la presente son útiles para el tratamiento de enfermedades relacionadas con PPARd (por ejemplo, enfermedades musculares, enfermedades vasculares, enfermedades desmielinizantes y enfermedades metabólicas).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238629P | 2015-10-07 | 2015-10-07 | |
| US201562243263P | 2015-10-19 | 2015-10-19 | |
| US201662352348P | 2016-06-20 | 2016-06-20 | |
| PCT/US2016/055521 WO2017062468A1 (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018004295A true MX2018004295A (es) | 2018-08-09 |
| MX380281B MX380281B (es) | 2025-03-12 |
Family
ID=57200096
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004295A MX380281B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmacéuticas y métodos de uso de agonistas de ppar. |
| MX2020011099A MX392524B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
| MX2020011100A MX392523B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011099A MX392524B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
| MX2020011100A MX392523B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US10399958B2 (es) |
| EP (3) | EP3359528B1 (es) |
| JP (2) | JP6657413B2 (es) |
| KR (2) | KR102667385B1 (es) |
| CN (3) | CN113004205B (es) |
| AU (3) | AU2016333963C1 (es) |
| BR (1) | BR112018006866B1 (es) |
| CA (1) | CA3000431A1 (es) |
| CO (1) | CO2018004473A2 (es) |
| DK (1) | DK3359528T3 (es) |
| EA (1) | EA037371B1 (es) |
| ES (3) | ES2906379T3 (es) |
| HU (1) | HUE058154T2 (es) |
| IL (3) | IL258225B (es) |
| JO (3) | JO3738B1 (es) |
| MA (2) | MA52098A (es) |
| MX (3) | MX380281B (es) |
| MY (1) | MY203081A (es) |
| PH (1) | PH12018500762A1 (es) |
| PL (1) | PL3359528T3 (es) |
| PT (1) | PT3359528T (es) |
| SG (1) | SG10201906400SA (es) |
| TW (3) | TWI730408B (es) |
| UA (1) | UA122237C2 (es) |
| WO (1) | WO2017062468A1 (es) |
| ZA (4) | ZA201802029B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102667385B1 (ko) * | 2015-10-07 | 2024-05-21 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| HRP20210294T1 (hr) * | 2016-10-05 | 2021-04-16 | Mitobridge, Inc. | Postupci liječenja akutnog bubrežnog oštećenja |
| EP3523283B1 (en) | 2016-10-05 | 2021-06-09 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| WO2021046081A1 (en) * | 2019-09-05 | 2021-03-11 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| MX2023010537A (es) * | 2021-03-08 | 2023-11-28 | Abionyx Pharma Sa | Compuestos útiles para tratar enfermedades del hígado. |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| BR112023025221A2 (pt) | 2021-06-02 | 2024-02-27 | Astellas Pharma Inc | Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2025207099A1 (en) | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
| DE4123341A1 (de) | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| WO2000050391A1 (en) | 1999-02-26 | 2000-08-31 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| CA2419633C (en) | 2000-08-17 | 2011-05-10 | Pfizer Inc. | Substituted imidazoles as tafia inhibitors |
| AU2003265681A1 (en) * | 2002-08-29 | 2004-03-19 | Merck And Co., Inc. | Indoles having anti-diabetic activity |
| US7820682B2 (en) | 2002-10-03 | 2010-10-26 | Ono Pharmaceutical Co., Ltd. | LPA receptor antagonist |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| WO2005030185A2 (en) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
| CA2577608A1 (en) | 2004-09-06 | 2006-03-16 | F. Hoffmann-La Roche Ag | 4-aminomethyl benzamidine derivatives and their use as factor viia inhibitors |
| WO2007028424A1 (en) | 2005-02-15 | 2007-03-15 | F. Hoffmann-La Roche Ag | Amide derivatives as ppar activators |
| WO2007030567A2 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
| AU2007211319B9 (en) | 2006-01-30 | 2012-05-31 | Vtv Therapeutics Llc | Substituted imidazole derivatives and their use as PTPase inhibitors |
| JP2009531364A (ja) | 2006-03-28 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | アミド誘導体およびｇタンパク質関連疾患の処置のためのそれらの使用 |
| NZ572268A (en) | 2006-04-18 | 2011-09-30 | Nippon Chemiphar Co | Activating agent for peroxisome proliferator activated receptor delta (ppar) |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| CN101085772A (zh) | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008221718A1 (en) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
| AU2008345009A1 (en) | 2007-12-28 | 2009-07-09 | The Salk Institute For Biological Studies | Methods for enhancing muscle performance and tone |
| JP5895104B2 (ja) | 2012-08-28 | 2016-03-30 | コチ・ウニヴェルシテシＫｏｃ Ｕｎｉｖｅｒｓｉｔｅｓｉ | 骨板 |
| CA2908695A1 (en) | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Ppar agonists |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| KR102667385B1 (ko) | 2015-10-07 | 2024-05-21 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| HRP20210294T1 (hr) | 2016-10-05 | 2021-04-16 | Mitobridge, Inc. | Postupci liječenja akutnog bubrežnog oštećenja |
| EP3523283B1 (en) * | 2016-10-05 | 2021-06-09 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| MA47165B1 (fr) * | 2016-12-30 | 2021-06-30 | Mitobridge Inc | Inhibiteurs de la poly-adp-ribose polymérase (parp) |
-
2016
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en not_active Ceased
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/en active Active
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-09-14 JO JOP/2020/0230A patent/JOP20200230A1/ar unknown
- 2020-09-14 JO JOP/2020/0231A patent/JOP20200231A1/ar unknown
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
-
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004295A (es) | Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar. | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| CL2016001895A1 (es) | Compuestos | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2018012538A (es) | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| MX2020003495A (es) | Derivados de acido boronico y sintesis de los mismos. | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| CO2017002312A2 (es) | Compuestos bicíclicos sustituidos | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| CL2017003025A1 (es) | Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios. | |
| CL2018002848A1 (es) | Formulaciones liquidas de fosfoplatino | |
| WO2016057660A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| CL2018000336A1 (es) | Composición para el tratamiento de la mucosidad en las branquias de los peces | |
| EA201992618A2 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |